|
Originally published In Press as doi:10.1074/jbc.M110312200 on April 3, 2002
J. Biol. Chem., Vol. 277, Issue 24, 21423-21430, June 14, 2002
Functional Consequences of the Loss of High Affinity Agonist
Binding to -Aminobutyric Acid Type A Receptors
IMPLICATIONS FOR RECEPTOR DESENSITIZATION*
J. Glen
Newell § and
Susan M. J.
Dunn ¶
From the Department of Pharmacology and ¶ Centre
for Neuroscience, University of Alberta, Edmonton,
Alberta T6G 2H7, Canada
We reported previously that tyrosine
62 of the 2 subunit of the -aminobutyric acid, type A
(GABAA) receptor is an important determinant of high
affinity agonist binding and that recombinant 1 2 2L
receptors carrying the Y62S mutation lack measurable high affinity
sites for [3H]muscimol. We have now examined the effects
of disrupting these sites on the macroscopic desensitization properties
of receptors expressed in Xenopus oocytes. Desensitization
was measured by the ability of low concentrations of bath-perfused
agonist to reduce the current responses elicited by subsequent
challenges with saturating concentrations of GABA. Wild-type receptors
were desensitized by pre-perfused muscimol with an IC50
~0.7 µM, which correlates well with the lower affinity
sites for this agonist that are measured in direct binding studies.
Receptors carrying the 2 Y62S and Y62F mutations desensitized at
slightly higher (2-7-fold) agonist concentrations. However, at low
perfusate concentrations, the Y62S-containing receptor recovered from
the desensitized state even in the continued presence of agonist. The
characteristics of desensitization in the wild-type and mutant
receptors lead us to suggest that the major role of the high affinity
agonist-binding site(s) of the GABAA receptor is not to
induce desensitization but rather to stabilize the desensitized state
once it has been formed.
*
This work was supported in part by the Canadian Institutes
of Health Research.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by the Natural Sciences and Engineering Research Council
of Canada, the NeuroScience Canada Foundation, and the Alberta Heritage
Foundation for Medical Research. Present address: Dept. of Physiology,
University of Wisconsin, 1300 University Ave., Madison, WI 53706.
To whom correspondence should be addressed: Dept. of
Pharmacology, School of Medical Sciences, University of Bristol,
Bristol BS8 1TD, UK. Tel.: 44-117-928-8092; Fax: 44-117-9250168;
E-mail: susan.dunn@bristol.ac.uk.
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. B. Pratt, T. S. Brink, P. Bergson, M. M. Voigt, and S. P. Cook
Use-Dependent Inhibition of P2X3 Receptors by Nanomolar Agonist
J. Neurosci.,
August 10, 2005;
25(32):
7359 - 7365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Baumann, R. Baur, and E. Sigel
Forced Subunit Assembly in alpha 1beta 2gamma 2 GABAA Receptors. INSIGHT INTO THE ABSOLUTE ARRANGEMENT
J. Biol. Chem.,
November 22, 2002;
277(48):
46020 - 46025.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|